FDA Approves Sorilux for Adolescent Plaque Psoriasis
The US Food and Drug Administration (FDA) has approved SORILUX (calcipotriene) Foam, 0.005% in adolescents.
The US Food and Drug Administration (FDA) has approved SORILUX (calcipotriene) Foam, 0.005% in adolescents.
A Galderma-supported clinical trial compared two treatment sequences using Restylane Skinboosters and Sculptra to determine which produced greater improvements in skin hydration and remodeling among menopausal women.